A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Escalating Study to Assess the Pharmacokinetics and Pharmacodynamics of MTR105 in Cardiac Surgery Induced Hypotension Patients During Weaning Off Cardiopulmonary Bypass
Latest Information Update: 06 Nov 2021
At a glance
- Drugs MTR 104 (Primary)
- Indications Hypotension
- Focus Pharmacodynamics
- Sponsors Meditor Pharmaceuticals
Most Recent Events
- 03 Nov 2014 New trial record